| 股票 | 标签 | 申万二级 | PE | 前瞻PE | PEG | PB | 股息率 | 分红率 | 毛利率 | 固定资产 | 债/EBITDA | FCF/市值 | 营收3年 | 去年 | YTD | 近一年 | 回撤 | 波动 | 市值亿 ▾ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 新产业 300832 | 定价权·品牌 | 医疗器械 | 23.6 | 21.8 | 1.28 | 4.51 | 2.3% | 56% | 71% | 18% | 0.0 | 4.1% | +14% | -20% | -6% | -13% | -43% | 34% | 405 |
| 万泰生物 603392 | 亏损或困境 | 医疗器械 | — | — | — | 2.98 | — | 32% | 86% | 24% | — | -1.5% | -45% | -36% | -38% | -56% | -57% | 36% | 350 |
| 九安医疗 002432 | 中性 | 医疗器械 | 7.1 | — | — | 1.36 | 2.2% | 11% | 64% | 1% | — | -1.9% | -63% | -1% | +76% | +68% | -39% | 64% | 315 |
| 安图生物 603658 | 现金流红利 | 医疗器械 | 19.0 | 16.7 | 1.19 | 2.17 | 4.0% | 70% | 65% | 31% | 0.0 | 3.4% | -2% | -17% | -3% | -20% | -30% | 23% | 188 |
| 圣湘生物 688289 | 纯久期 | 医疗器械 | 68.4 | 35.8 | 1.70 | 1.31 | 3.3% | 112% | 72% | 13% | 5.5 | -0.6% | -37% | -15% | -14% | -27% | -36% | 35% | 92 |
| 热景生物 688068 | 亏损或困境 | 医疗器械 | — | — | — | 3.58 | — | 64% | 57% | 29% | — | -3.5% | -52% | +162% | -42% | -62% | -68% | 73% | 87 |
| 中源协和 600645 | 纯久期 | 医疗器械 | 74.4 | — | — | 2.33 | — | — | 69% | 10% | 0.2 | 3.2% | -2% | +31% | -26% | -34% | -49% | 44% | 87 |
| 万孚生物 300482 | 亏损或困境 | 医疗器械 | — | 20.0 | 1.11 | 1.47 | 1.3% | 35% | 58% | 20% | 5.2 | 8.7% | -28% | -10% | -14% | -27% | -38% | 44% | 78 |
| 英诺特 688253 | 纯久期 | 医疗器械 | 154.8 | — | — | 3.85 | 0.8% | 31% | 77% | 5% | 0.1 | 0.3% | -2% | -16% | +92% | +75% | -24% | 54% | 78 |
| 达安基因 002030 | 亏损或困境 | 医疗器械 | — | — | — | 1.08 | — | 20% | 50% | 18% | 1.9 | 2.8% | -60% | +5% | -9% | -24% | -37% | 42% | 76 |
| 九强生物 300406 | 成长兑现 | 医疗器械 | 30.7 | 16.9 | 0.77 | 2.01 | 8.9% | 44% | 75% | 10% | 2.0 | 7.8% | -4% | +5% | -4% | -14% | -26% | 29% | 69 |
| 艾德生物 300685 | 定价权·品牌 | 医疗器械 | 19.8 | 16.2 | 1.01 | 3.53 | 2.6% | 47% | 84% | 8% | 0.4 | 4.9% | +12% | -9% | -14% | -30% | -36% | 37% | 67 |
| 浩欧博 688656 | 中性 | 医疗器械 | 239.5 | — | — | 7.98 | 0.2% | 54% | 63% | 71% | 0.3 | 0.8% | +8% | +62% | -32% | -16% | -63% | 55% | 66 |
| 亚辉龙 688575 | 中性 | 医疗器械 | 86.0 | 34.1 | 1.18 | 2.10 | 0.2% | 43% | 57% | 39% | 1.8 | 2.8% | -23% | -9% | -29% | -38% | -48% | 33% | 58 |
| 博拓生物 688767 | 中性 | 医疗器械 | 275.9 | 54.6 | 2.60 | 2.62 | 1.9% | 186% | 53% | 24% | 1.8 | -1.3% | -38% | +70% | +1% | -7% | -37% | 61% | 56 |
| 迈克生物 300463 | 亏损或困境 | 医疗器械 | — | 73.9 | 0.74 | 0.89 | — | 40% | 55% | 48% | 2.5 | 1.3% | -16% | -15% | -17% | -28% | -43% | 32% | 56 |
| 普门科技 688389 | 定价权·品牌 | 医疗器械 | 33.8 | 22.2 | 1.01 | 2.31 | 2.5% | 36% | 63% | 22% | 1.2 | 4.0% | +2% | -11% | -12% | -21% | -34% | 26% | 48 |
| 基蛋生物 603387 | 中性 | 医疗器械 | 15.9 | — | — | 1.60 | 2.6% | 41% | 67% | 19% | 0.9 | 6.6% | -17% | +4% | +13% | +8% | -28% | 38% | 47 |
| 东方生物 688298 | 亏损或困境 | 医疗器械 | — | — | — | 0.66 | — | — | 43% | 38% | — | -10.5% | -52% | -20% | -19% | -36% | -41% | 34% | 38 |
| 凯普生物 300639 | 亏损或困境 | 医疗器械 | — | — | — | 1.00 | — | 26% | 61% | 30% | 0.7 | 5.4% | -51% | -9% | +10% | -12% | -45% | 50% | 38 |
| 安旭生物 688075 | 纯久期 | 医疗器械 | — | — | — | 0.74 | 2.7% | 80% | 42% | 14% | 2.9 | -3.4% | -58% | +7% | -23% | -30% | -38% | 26% | 37 |
| *ST明德 002932 | 亏损或困境 | 医疗器械 | — | — | — | 0.67 | — | 204% | 54% | 11% | — | -2.4% | -71% | +12% | -19% | -28% | -36% | 28% | 36 |
| 美康生物 300439 | 中性 | 医疗器械 | 52.1 | — | — | 1.18 | 0.4% | 20% | 40% | 30% | 0.4 | 2.3% | -15% | -4% | -6% | -19% | -31% | 27% | 36 |
| 奥泰生物 688606 | 现金流红利 | 医疗器械 | 24.9 | — | — | 0.92 | 4.5% | 78% | 55% | 25% | 0.1 | 1.7% | -36% | +5% | -27% | -38% | -44% | 28% | 35 |
| 硕世生物 688399 | 亏损或困境 | 医疗器械 | — | — | — | 1.14 | 8.5% | — | 63% | 18% | 18.8 | -1.6% | -61% | +67% | -42% | -35% | -58% | 58% | 33 |
| 赛科希德 688338 | 中性 | 医疗器械 | 38.6 | 35.1 | 2.34 | 1.90 | 0.8% | 31% | 62% | 17% | — | 1.5% | +5% | +9% | +19% | +10% | -33% | 46% | 32 |
| 之江生物 688317 | 亏损或困境 | 医疗器械 | — | — | — | 0.99 | — | — | 62% | 16% | — | 0.9% | -62% | +24% | -16% | -42% | -45% | 45% | 32 |
| 利德曼 300289 | 亏损或困境 | 医疗器械 | — | — | — | 1.96 | — | 33% | 52% | 21% | 0.2 | 0.5% | -23% | +42% | -16% | -35% | -43% | 43% | 32 |
| 科华生物 002022 | 亏损或困境 | 医疗器械 | — | — | — | 1.19 | — | — | 42% | 17% | — | -3.9% | -38% | -6% | -4% | -22% | -38% | 31% | 29 |
| 丹娜生物 920009 | 中性 | 医疗器械 | 30.6 | 23.4 | 1.30 | 4.12 | 1.0% | 25% | 84% | 9% | 0.0 | 2.1% | -6% | — | -31% | — | — | — | 29 |
| 透景生命 300642 | 纯久期 | 医疗器械 | 228.4 | 216.5 | 1.34 | 1.96 | 0.9% | 70% | 66% | 19% | 4.7 | 4.8% | -20% | +32% | -5% | -39% | -64% | 59% | 28 |
| 易瑞生物 300942 | 亏损或困境 | 医疗器械 | — | 54.4 | 1.30 | 3.26 | 0.4% | 63% | 64% | 38% | 9.3 | -0.0% | -27% | +10% | -30% | -50% | -59% | 40% | 26 |
| 科美诊断 688468 | 中性 | 医疗器械 | 72.2 | — | — | 1.78 | — | 36% | 75% | 24% | 2.6 | 2.9% | -11% | +9% | -14% | -28% | -37% | 27% | 25 |
| 康为世纪 688426 | 亏损或困境 | 医疗器械 | — | — | — | 1.79 | — | — | 65% | 22% | — | -2.9% | -28% | -17% | -12% | -14% | -55% | 47% | 24 |
| ST迪瑞 300396 | 亏损或困境 | 医疗器械 | — | — | — | 1.26 | — | 96% | 52% | 7% | — | -4.6% | -13% | -20% | -44% | -53% | -60% | 36% | 20 |
| 仁度生物 688193 | 纯久期 | 医疗器械 | 108.8 | — | — | 2.17 | 2.3% | 269% | 78% | 7% | 0.1 | 0.7% | -19% | +37% | +1% | -12% | -33% | 41% | 19 |
| 安必平 688393 | 亏损或困境 | 医疗器械 | — | — | — | 1.67 | 0.5% | 39% | 68% | 18% | 0.4 | -0.1% | -12% | +38% | -14% | -38% | -53% | 46% | 19 |
| 爱威科技 688067 | 中性 | 医疗器械 | 49.1 | — | — | 3.04 | 0.6% | 31% | 59% | 21% | 1.0 | 1.9% | +4% | +48% | -4% | -14% | -38% | 36% | 16 |
| 睿昂基因 688217 | 亏损或困境 | 医疗器械 | — | — | — | 1.64 | 0.7% | 129% | 73% | 38% | 0.8 | 2.8% | -25% | +44% | -7% | -21% | -45% | 43% | 14 |
点表头排序。市值单位亿元;去年/YTD 为前复权涨幅;债/EBITDA = 有息负债 ÷ EBITDA。